Technology ID

Epstein-Barr Virus (EBV)-feeder Cell Line

Lead Inventor
Childs, Richard (NHLBI)
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Research Products
Human Cell Lines
Lead IC

This technology includes irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) as feeder cells for the ex vivo expansion of natural killer (NK) cells. EBV-LCL feeder cells, altered by radiation to prevent uncontrolled growth, provide a supportive environment for NK cells to multiply effectively. This method addresses the challenge of obtaining sufficient quantities of functionally active NK cells, which are crucial components of the immune system known for their ability to target and destroy tumor cells and virally infected cells. The use of EBV-LCL feeder cells permits improved scalability and effectiveness of NK cell-based therapies for cancer and infectious diseases.

Commercial Applications
This method potentially allows for a more efficient expansion of NK cells compared to current techniques, resulting in a higher yield of cells for therapeutic use.

Competitive Advantages
This technology offers a competitive advantage by enabling efficient and large-scale production of functionally active natural killer cells, enhancing the potential of NK cell-based therapies in treating cancer and infectious diseases.
Licensing Contact:
Shmilovich, Michael